Physician profile
Ramin Assadi
NPI 1942418793
$3,986.02
in general payments reported to CMS, 2019-2025
11 companies · $727 in 2025
The $727 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,603 · 2020: $124 · 2021: $173 · 2022: $788 · 2023: $344 · 2024: $227 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140 · Grant: $125 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.42 |
| Grant | $125.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $952.79 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biomarin Pharmaceutical INC. | $753.55 | 2019 | |
| Edwards Lifesciences Corporation | $561.50 | 2019 | |
| Abiomed | $466.26 | 2019-2025 | |
| Boston Scientific Corporation | $331.92 | 2023-2025 | Emerge Push, Rotablator Rotational Atherectomy System Console Kit, Synergy |
| Heartflow, INC. | $282.54 | 2025 | |
| Abbott Laboratories | $189.07 | 2022 | |
| Penumbra, INC. | $149.00 | 2022 | |
| Medtronic Vascular, INC. | $142.83 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.29 | 2020 | |
| Novo Nordisk INC | $32.27 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Assadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.